BioAge Labs announced that its lead candidate, BGE‑102, an oral NLRP3 inhibitor, completed a Phase 1 clinical trial in participants with obesity and elevated high‑sensitivity C‑reactive protein (hs‑CRP). The study demonstrated a robust safety profile, with no serious adverse events or dose‑dependent safety signals across all dose levels.
The trial showed median hs‑CRP reductions of ≥85 % for both the 120 mg and the newly introduced 60 mg once‑daily doses. At Day 7, the 60 mg cohort achieved an 85 % reduction and at Day 21 an 86 % reduction; the 120 mg cohort reached an 83 % reduction at Day 7 and an 86 % reduction at Day 14. Ninety‑three percent of subjects—13 out of 14—reached hs‑CRP levels below 2 mg/L, a threshold associated with reduced cardiovascular risk.
"These Phase 1 results position BGE‑102 as a potential best‑in‑class NLRP3 inhibitor, delivering profound hsCRP reductions with a well‑tolerated once‑daily oral dose," said Kristen Fortney, Ph.D., CEO and co‑founder. She added, "These data give us strong conviction to accelerate the program across multiple indications. BGE‑102’s potency and tissue penetration make it a potential pipeline in a pill—a single oral therapy to address NLRP3‑driven inflammation in cardiovascular, ocular, and CNS diseases." Chief Medical Officer Paul Rubin, M.D., noted, "Chronic inflammation is now recognized as a major driver of cardiovascular disease—on par with cholesterol—yet it remains far less commonly treated. An 86 % reduction in hsCRP, with 93 % of participants reaching levels associated with reduced cardiovascular risk, positions BGE‑102 as a potential best‑in‑class oral therapy to directly address inflammation. These findings support our plans to advance BGE‑102 into a Phase 2a study in the first half of this year. hsCRP is among the most predictive biomarkers of cardiovascular risk, and targeting inflammation is a clinically validated strategy: prior interventional data for anti‑inflammatory therapies demonstrated that reducing hsCRP below 2 mg/L was associated with a 25 % reduction in major adverse cardiovascular events."
The company plans to launch a Phase 2 cardiovascular‑risk proof‑of‑concept trial in the first half of 2026, with results expected in the second half of the year. In parallel, a Phase 1b/2a proof‑of‑concept study in diabetic macular edema (DME) patients is slated to begin in mid‑2026, with results anticipated in mid‑2027. These next‑step plans aim to validate BGE‑102’s target engagement across multiple indications and accelerate the drug’s development timeline.
BioAge’s announcement comes against a backdrop of a rapidly expanding NLRP3 inflammasome inhibitor market, projected to reach $9.8 billion by 2034. The company’s BGE‑102 is described as having a novel structure, brain‑penetrant properties, and a distinct binding site, setting it apart from competitors. BioAge has strategic collaborations with Novartis and Eli Lilly, underscoring external validation of its approach. The company’s balance sheet remains strong, with more cash than debt and liquid assets exceeding short‑term obligations; as of April 14, 2026, its market cap was $735.37 million.
The Phase 1 results reinforce BioAge’s “pipeline in a pill” strategy, positioning BGE‑102 as a single oral therapy that could address cardiovascular, ophthalmic, and neuroinflammatory diseases. The strong safety and efficacy profile, coupled with the company’s robust financial position and strategic partnerships, suggest a favorable trajectory for the drug’s development and potential market impact.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.